These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 16835991)

  • 1. [New catastrophe in pharmacological treatment--the crisis of clinical studies? Acute organ failure after administration of TGN1412].
    Jerie P
    Cas Lek Cesk; 2006; 145(6):426. PubMed ID: 16835991
    [No Abstract]   [Full Text] [Related]  

  • 2. London's disastrous drug trial has serious side effects for research.
    Wadman M
    Nature; 2006 Mar; 440(7083):388-9. PubMed ID: 16554763
    [No Abstract]   [Full Text] [Related]  

  • 3. Agency criticises drug trial.
    Day M
    BMJ; 2006 Jun; 332(7553):1290. PubMed ID: 16740539
    [No Abstract]   [Full Text] [Related]  

  • 4. High stakes, high risks.
    Lancet Oncol; 2007 Feb; 8(2):85. PubMed ID: 17267317
    [No Abstract]   [Full Text] [Related]  

  • 5. Does the TGN1412 trial disaster have lessons for clinical trials in India?
    George T; Srinivasan S
    Natl Med J India; 2006; 19(5):283-6. PubMed ID: 17203685
    [No Abstract]   [Full Text] [Related]  

  • 6. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.
    Suntharalingam G; Perry MR; Ward S; Brett SJ; Castello-Cortes A; Brunner MD; Panoskaltsis N
    N Engl J Med; 2006 Sep; 355(10):1018-28. PubMed ID: 16908486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytokine storm and an anti-CD28 monoclonal antibody.
    Gardner K
    N Engl J Med; 2006 Dec; 355(24):2591-2; author reply 2593-4. PubMed ID: 17171819
    [No Abstract]   [Full Text] [Related]  

  • 8. Learning from the TGN1412 trial.
    Goodyear M
    BMJ; 2006 Mar; 332(7543):677-8. PubMed ID: 16554332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimising risk in first-in-man trials.
    Hemelaar J
    Lancet; 2007 May; 369(9572):1496-1497. PubMed ID: 17482966
    [No Abstract]   [Full Text] [Related]  

  • 10. Pathogenesis of multi-organic failure in autoimmune diseases.
    Amaral MC; Alves JD
    Autoimmun Rev; 2009 May; 8(6):525-8. PubMed ID: 19186222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Further lessons from the TGN1412 tragedy.
    Goodyear MD
    BMJ; 2006 Aug; 333(7562):270-1. PubMed ID: 16888292
    [No Abstract]   [Full Text] [Related]  

  • 12. TeGenero fiasco prompts regulatory rethink.
    Sheridan C
    Nat Biotechnol; 2006 May; 24(5):475-6. PubMed ID: 16680111
    [No Abstract]   [Full Text] [Related]  

  • 13. Some aspects of the recombinantly expressed humanised superagonist anti-CD28 mAb, TGN1412 trial catastrophe lessons to safeguard mAbs and vaccine trials.
    Mehrishi JN; Szabó M; Bakács T
    Vaccine; 2007 May; 25(18):3517-23. PubMed ID: 17397974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Volunteers at risk.
    Drazen JM
    N Engl J Med; 2006 Sep; 355(10):1060-1. PubMed ID: 16908488
    [No Abstract]   [Full Text] [Related]  

  • 15. CD28 superagonists: what makes the difference in humans?
    Schraven B; Kalinke U
    Immunity; 2008 May; 28(5):591-5. PubMed ID: 18482560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Firm involved in drug trial fiasco files for bankruptcy.
    Dyer O
    BMJ; 2006 Jul; 333(7559):114. PubMed ID: 16840457
    [No Abstract]   [Full Text] [Related]  

  • 17. Cytokine storm and an anti-CD28 monoclonal antibody.
    Takita M; Matsumura T; Kami M
    N Engl J Med; 2006 Dec; 355(24):2593; author reply 2593-4. PubMed ID: 17171821
    [No Abstract]   [Full Text] [Related]  

  • 18. TGN1412: time to change the paradigm for the testing of new pharmaceuticals.
    Bhogal N; Combes R
    Altern Lab Anim; 2006 May; 34(2):225-39. PubMed ID: 16704293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TGN1412: the catalyst for change?
    Altern Lab Anim; 2006 Aug; 34(4):369-71. PubMed ID: 16969950
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunostimulatory antibodies: challenging the drug testing paradigm.
    Bhogal N; Combes R
    Toxicol In Vitro; 2007 Oct; 21(7):1227-32. PubMed ID: 17434714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.